Lexeo Therapeutics, Inc. Convertible Notes Payable, Current
Lexeo Therapeutics, Inc. (LXEO) had Convertible Notes Payable, Current of $4.15 million as of 2023-09-30, per its 10-Q filed 2023-12-11.
Discontinued › Balance Sheet › Liabilities, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2023-12-11
- 2023-09-30: Convertible Notes Payable, Current $4.15M.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2023-09-30 | $4.15M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |